摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-叔丁氧羰基-5-羟基色氨酸甲酯 | 203736-17-8

中文名称
N-叔丁氧羰基-5-羟基色氨酸甲酯
中文别名
——
英文名称
(S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(5-hydroxy-1H-indol-3-yl)propanoate
英文别名
n-Boc-5-hydroxytryptophan methyl ester;methyl (2S)-3-(5-hydroxy-1H-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
N-叔丁氧羰基-5-羟基色氨酸甲酯化学式
CAS
203736-17-8
化学式
C17H22N2O5
mdl
——
分子量
334.372
InChiKey
XNPXNIXOCSKSGI-AWEZNQCLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    555.9±50.0 °C(Predicted)
  • 密度:
    1.262±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    24
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    101
  • 氢给体数:
    3
  • 氢受体数:
    5

SDS

SDS:45241f8a67dc2479c7d2e974341f460e
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency
    摘要:
    Optimization of benzimidazole 5-carboxamide derivatives previously identified as specific inhibitors of the NS5B polymerase of the hepatitis C virus (HCV) has led to the discovery of potent analogues that inhibit the enzyme at low-nanomolar concentrations. Greater than 800-fold improvement in potency from the original lead structure was achieved through the combined effects of conformational rigidification, molecular size extension and the identification of previously unexploited interactions. Furthermore, these inhibitors retain specificity for HCV polymerase relative to other viral and mammalian RNA polymerases. (C) 2003 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2003.12.032
  • 作为产物:
    描述:
    5-羟基-L-色氨酸氯化亚砜碳酸氢钠 作用下, 以 1,4-二氧六环 为溶剂, 反应 4.0h, 生成 N-叔丁氧羰基-5-羟基色氨酸甲酯
    参考文献:
    名称:
    开发用于DNA甲基转移酶1(DNMT 1)的新化学工具:基于小分子活性的探针和新型含四唑的抑制剂
    摘要:
    DNA甲基化是DNA甲基转移酶(DNMT)催化的重要表观遗传修饰。人体内内源性DNMT的异常表达会导致基因组甲基化模式的改变,进而导致癌症的发展。因此,检测内源性DNMT活性和有效抑制DNMT具有重要的治疗意义。在这项工作中,开发了一种基于小分子活性的DNA甲基转移酶1(DNMT1)T1探针(ABP)。该探针是色氨酸的可点击类似物,能够共价标记内源性DNMT1并比以前已知的DNMT1抑制剂(RG108及其马来酰亚胺类似物1149)更有效地抑制其酶促活性。)。此外,我们还发现了一种新型的小分子DNMT抑制剂,其基于含四唑的化合物,该化合物是1149的类似物。在我们称为Gn的这些化合物中,其中之一(G6)在体外酶促测定和细胞生长增殖实验中均具有对DNMT1的合理抑制活性。既T1和G6显示从哺乳动物细胞中内源性DNMT1的有效标记通过使用体外竞争下拉和活细胞生物成像实验。
    DOI:
    10.1016/j.bmc.2015.03.006
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL AGENTS TARGETING CYP51<br/>[FR] NOUVEAUX AGENTS CIBLANT CYP51
    申请人:SCRIPPS RESEARCH INST
    公开号:WO2015048306A1
    公开(公告)日:2015-04-02
    The invention provides inhibitors of a sterol C14-demethylase, a new series of 4- aminopyridyl-based lead inhibitors targeting Trypanosoma cruzi CYP51 (TcCYP51) developed using structure-based drug design as well as structure -property relationship (SPR) analyses. The screening hit starting point, LP 10 (KD < 42 nM; EC50 of 0.65 μΜ), has been optimized to give the potential leads that have low nanomolar binding affinity to TcCYP51 and significant activity against T. cruzi amastigotes cultured in human myoblasts. Many of the optimized compounds have improved microsome stability, and most are selective against the T. cruzi CYP51 relative to human CYPs 1A2, 2D6 and 3A4 (<50% inhibition at 1 μΜ). A rationale for the improvement of microsome stability and selectivity of inhibitors against human metabolic CYP enzymes is presented. In addition, the binding mode of several compounds of the invention with the T. brucei CYP51 (TbCYP51) ortholog has been characterized by x-ray structure analysis. Orally active compounds and their cyclodextrin complexes have been shown to be effective against Chagas-infected mice.
    该发明提供了一种甾醇C14-去甲基酶的抑制剂,这是一种新系列基于4-氨基吡啶的首选抑制剂,通过基于结构的药物设计以及结构-性质关系(SPR)分析来瞄准Trypanosoma cruzi CYP51(TcCYP51)而开发的。筛选起始点LP 10(KD < 42 nM;EC50为0.65 μΜ)已经经过优化,产生了具有低纳摩尔级别结合亲和力和对在人类肌细胞培养的T. cruzi游离体的显著活性的潜在首选抑制剂。许多经过优化的化合物具有改善的微粒体稳定性,大多数相对于人类CYPs 1A2、2D6和3A4对T. cruzi CYP51具有选择性(在1 μΜ下<50%的抑制)。提出了改善微粒体稳定性和抑制剂对人类代谢CYP酶的选择性的理由。此外,通过X射线结构分析表征了该发明的几种化合物与T. brucei CYP51(TbCYP51)同源物的结合方式。口服活性化合物及其环糊精复合物已被证明对克氏病感染的小鼠有效。
  • Kinase inhibitors
    申请人:——
    公开号:US20030187026A1
    公开(公告)日:2003-10-02
    Compounds having the formula 1 are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.
    具有以下化学式的化合物对抑制蛋白激酶很有用。还公开了抑制蛋白激酶的组合物以及在患者中抑制蛋白激酶的方法。
  • MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY
    申请人:University of Kentucky Research Foundation
    公开号:US20190083519A1
    公开(公告)日:2019-03-21
    Mithramycin side chain carboxylic acid (MTM-SA) derivative are provided, which include a substituted amino acid derivative, a substituted amino acid dipeptide derivative, or an unsubstituted dipeptide derivative. The MTM-SA derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM-SA derivatives have increased selectively toward ETS transcription factor.
    米司麦霉素侧链羧酸(MTM-SA)衍生物包括一种取代氨基酸衍生物、一种取代氨基酸二肽衍生物或一种未取代的二肽衍生物。这些MTM-SA衍生物对于治疗与异常红细胞转化特异性转录因子相关的癌症或神经疾病很有用。独特的MTM-SA衍生物对ETS转录因子具有增强的选择性。
  • Viral polymerase inhibitors
    申请人:——
    公开号:US20020065418A1
    公开(公告)日:2002-05-30
    A compound of the formula I: 1 wherein: X is CH or N; Y is O or S; Z is OH, NH 2 , NMeR 3 , NHR 3 ; OR 3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from 0, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR 7 or CR 5 , wherein R 5 is H, halogen, or (C 1-6 ) alkyl and R 7 is H or (C 1-6 alkyl), with the proviso that X and A are not both N; R 6 is H, halogen, (C 1-6 alkyl) or OR 7 , wherein R 7 is H or (C 1-6 alkyl); R 1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C 1-3 )alkyl, (C 2-6 )alkenyl, phenyl(C 2-6 )alkenyl, (C 3-6 )cycloalkyl, (C 1-6 )alkyl, CF 3 , 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C 2-6 )alkenyl and phenyl(C 1-3 )alkyl), alkenyl, cycloalkyl, (C 1-6 )alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents R 2 is selected from (C 1-6 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-3 )alkyl, (C 6-10 )bicycloalkyl, adamantyl, phenyl, and pyridyl, all of which is optionally substituted with from1 to 4 substituents; R 3 is selected from H, (C 1-6 )alkyl, (C 3-6 )cycloalkyl, (C 3 6 )cycloalkyl(C 1-6 )alkyl, (C 6-10 )aryl, (C 6-10 )aryl(C 1-6 )alkyl, (C 2-6 )alkenyl, (C 3-6 )cycloalkyl(C 2-6 )alkenyl, (C 6-10 )aryl(C 2-6 )alkenyl, N{(C 1-6 )alkyl} 2 , NHCOO(C 1-6 )alkyl(C 6-10 )aryl, NHCO(C 6-10 )aryl, (C 1-6 )alkyl-5- or 10-atom heterocycle, having 1 to 4 heteroatoms selected from O, N and S, and 5- or 10-atom heterocycle having 1 to 4 heteroatoms selected from O, N and S; wherein said alkyl, cycloalkyl, aryl, alkenyl and heterocycle are all optionally substituted with from 1 to 4 substituents; n is zero or 1; or a detectable derivative or salt thereof. The compounds of the invention may be used as inhibitors of hepatitis C virus replication. The invention further provides a method for treating or preventing hepatitis C virus infection.
    该化合物的结构式为I:1,其中:X为CH或N;Y为O或S;Z为OH、NH2、NMeR3、NHR3、OR3或含有1至4个异原子(0、N和S)的5-或6-成员杂环,该杂环可选择性地与1至4个取代基取代;A为N、COR7或CR5,其中R5为H、卤素或(C1-6)烷基,R7为H或(C1-6)烷基,但X和A不能同时为N;R6为H、卤素、(C1-6)烷基或OR7,其中R7为H或(C1-6)烷基;R1选自包括含有1至4个异原子(O、N和S)的5-或6-成员杂环、苯基、苯基(C1-3)烷基、(C2-6)烯基、苯基(C2-6)烯基、(C3-6)环烷基、(C1-6)烷基、CF3、含有1至4个异原子(O、N和S)的9-或10-成员杂环的群体,其中该杂环、苯基、苯基(C2-6)烯基和苯基(C1-3)烷基、烯基、环烷基、(C1-6)烷基和杂环均可选择性地与1至4个取代基取代;R2选自(C1-6)烷基、(C3-7)环烷基、(C3-7)环烷基(C1-3)烷基、(C6-10)双环烷基、金刚烷基、苯基和吡啶基,所有这些基均可选择性地与1至4个取代基取代;R3选自H、(C1-6)烷基、(C3-6)环烷基、(C3-6)环烷基(C1-6)烷基、(C6-10)芳基、(C6-10)芳基(C1-6)烷基、(C2-6)烯基、(C3-6)环烷基(C2-6)烯基、(C6-10)芳基(C2-6)烯基、N(C1-6)烷基2、NHCOO(C1-6)烷基(C6-10)芳基、NHCO(C6-10)芳基、(C1-6)烷基-含有1至4个异原子(O、N和S)的5-或10-原子杂环和含有1至4个异原子(O、N和S)的5-或10-原子杂环;其中所述烷基、环烷基、芳基、烯基和杂环均可选择性地与1至4个取代基取代;n为零或1;或其可检测衍生物或盐。该发明的化合物可用作乙型肝炎病毒复制的抑制剂。该发明还提供了一种治疗或预防乙型肝炎病毒感染的方法。
  • An Enantioselective Recyclable Polystyrene-Supported Threonine-Derived Organocatalyst for Aldol Reactions
    作者:Andrea H. Henseler、Carles Ayats、Miquel A. Pericàs
    DOI:10.1002/adsc.201400033
    日期:2014.5.26
    amino acids covalently supported onto polystyrene through alkyne–azide cycloaddition reactions has been synthesized and evaluated as catalysts in asymmetric aldol reactions. A polymer‐supported threonine behaves as an easily recyclable, highly reactive and stereoselective (up to 99% ee) catalyst in the aldol reaction of both cyclic and acyclic ketone donors with aromatic aldehydes in aqueous environments
    合成了一系列通过炔-叠氮化物环加成反应共价负载在聚苯乙烯上的伯氨基酸,并作为不对称羟醛反应的催化剂进行了评估。在水性环境中,环状和非环状酮供体与芳族醛的醛醇缩合反应中,聚合物负载的苏氨酸可作为易于回收,高反应性和立体选择性(高达99%ee)的催化剂。而环状酮与反应反非对映选择性,顺式加成物主要与无环的基材而获得。苏氨酸杂化催化剂已用于对映纯的醛醇缩醛产物的小型文库的顺序合成。
查看更多

同类化合物

(Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (R)-(+)-5'-苄氧基卡维地洛 (R)-卡洛芬 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (3Z)-3-(1H-咪唑-5-基亚甲基)-5-甲氧基-1H-吲哚-2-酮 (3Z)-3-[[[4-(二甲基氨基)苯基]亚甲基]-1H-吲哚-2-酮 (3R)-(-)-3-(1-甲基吲哚-3-基)丁酸甲酯 (3-氯-4,5-二氢-1,2-恶唑-5-基)(1,3-二氧代-1,3-二氢-2H-异吲哚-2-基)乙酸 齐多美辛 鸭脚树叶碱 鸭脚木碱,鸡骨常山碱 鲜麦得新糖 高氯酸1,1’-二(十六烷基)-3,3,3’,3’-四甲基吲哚碳菁 马鲁司特 马来酸阿洛司琼 马来酸替加色罗 顺式-ent-他达拉非 顺式-1,3,4,4a,5,9b-六氢-2H-吡啶并[4,3-b]吲哚-2-甲酸乙酯 顺式-(+-)-3,4-二氢-8-氯-4'-甲基-4-(甲基氨基)-螺(苯并(cd)吲哚-5(1H),2'(5'H)-呋喃)-5'-酮 靛红联二甲酚 靛红磺酸钠 靛红磺酸 靛红乙烯硫代缩酮 靛红-7-甲酸甲酯 靛红-5-磺酸钠 靛红-5-磺酸 靛红-5-硫酸钠盐二水 靛红-5-甲酸甲酯 靛红 靛玉红3'-单肟5-磺酸 靛玉红-3'-单肟 靛玉红 青色素3联己酸染料,钾盐 雷马曲班 雷莫司琼杂质13 雷莫司琼杂质12 雷莫司琼杂质 雷替尼卜定 雄甾-1,4-二烯-3,17-二酮 阿霉素的代谢产物盐酸盐 阿贝卡尔 阿西美辛叔丁基酯 阿西美辛 阿莫曲普坦杂质1 阿莫曲普坦 阿莫曲坦二聚体杂质 阿莫曲坦 阿洛司琼杂质